drugset / Trial / NCT00504205
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
Treatment
Summary
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable or metastatic refractory solid tumor, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-12
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amuvatinib | Small molecule | — | Oral |